James E Loyd

List of Publications by Year in descending order

178 papers	30,626 citations	8732 75 h-index	4535 171 g-index
184 all docs	184 docs citations	184 times ranked	19387 citing authors

#	Article	IF	Citations
1	CD4+CTLs in Fibrosing Mediastinitis Linked to Histoplasma capsulatum. Journal of Immunology, 2021, 206, 524-530.	0.4	17
2	Case series of pediatric mediastinal granuloma related to histoplasmosis. Pediatric Pulmonology, 2021, 56, 2958-2965.	1.0	1
3	A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1291-1297.	1.5	4
4	Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-11.	0.8	9
5	Heritable and Idiopathic Forms of Pulmonary Arterial Hypertension. , 2020, , 439-462.		2
6	Expression of a Human Caveolin-1 Mutation in Mice Drives Inflammatory and Metabolic Defect-Associated Pulmonary Arterial Hypertension. Frontiers in Medicine, 2020, 7, 540.	1.2	5
7	Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a caseâ€“control study. Pulmonary Circulation, 2020, 10, 1-9.	0.8	3
8	Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis. Science Advances, 2020, 6, eaba1972.	4.7	571
9	Development and Progression of Radiologic Abnormalities in Individuals at Risk for Familial Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1230-1239.	2.5	68
10	FHIT, a Novel Modifier Gene in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 83-98.	2.5	39
11	MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis. Thorax, 2019, 74, 1131-1139.	2.7	43
12	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	2.5	90
13	Genetics and genomics of pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801899.	3.1	306
14	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respiratory Medicine,the, 2018, 6, 154-160.	5.2	137
15	Aberrant Caveolin-1-Mediated Smad Signaling and Proliferation Identified by Analysis of Adenine 474 Deletion Mutation (c.474delA) in Patient Fibroblasts: A New Perspective in the Mechanism of Pulmonary Hypertension. Molecular Biology of the Cell, 2018, , mbc.E16-06-0380.	0.9	1
16	Genome-Wide Association Study of 58 Individuals with Fibrosing Mediastinitis Reveals Possible Underlying Genetic Susceptibility. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1219-1220.	2.5	2
17	Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e116-e136.	2.5	49
18	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702638.	3.1	183

#	Article	IF	Citations
19	T<scp>ranslational</scp> A<scp>dvances</scp> <scp>in</scp> <scp>the</scp> F<scp>ield</scp> <scp>of</scp> P<scp>ulmonary</scp> H<scp>ypertension</scp> Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 23-31.	2.5	32
20	Rare Genetic Variants in PARN Are Associated with Pulmonary Fibrosis in Families. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1481-1484.	2.5	31
21	Pulmonary arterial hypertension: Specialistsâ€™ knowledge, practices, and attitudes of genetic counseling and genetic testing in the USA. Pulmonary Circulation, 2017, 7, 372-383.	0.8	12
22	Genetics of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 585-595.	0.8	8
23	A disease-associated frameshift mutation in caveolin-1 disrupts caveolae formation and function through introduction of a de novo ER retention signal. Molecular Biology of the Cell, 2017, 28, 3095-3111.	0.9	37
24	Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects. European Respiratory Journal, 2017, 50, 1602337.	3.1	55
25	Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1423-1428.	2.5	71
26	Aberrant caveolin-1â€“mediated Smad signaling and proliferation identified by analysis of adenine 474 deletion mutation (c.474delA) in patient fibroblasts: a new perspective on the mechanism of pulmonary hypertension. Molecular Biology of the Cell, 2017, 28, 1177-1185.	0.9	30
27	Disruption of lineage specification in adult pulmonary mesenchymal progenitor cells promotes microvascular dysfunction. Journal of Clinical Investigation, 2017, 127, 2262-2276.	3.9	35
28	Reply: The Genetic Diagnosis of Interstitial Lung Disease: A Need for an International Consensus. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1539-1540.	2.5	1
29	Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia. BMC Genetics, 2016, 17, 74.	2.7	84
30	Shared Gene Expression Patterns in Mesenchymal Progenitors Derived from Lung and Epidermis in Pulmonary Arterial Hypertension: Identifying Key Pathways in Pulmonary Vascular Disease. Pulmonary Circulation, 2016, 6, 483-497.	0.8	19
31	Letter to Editor. IJC Heart and Vasculature, 2016, 13, 1-2.	0.6	0
32	Valsalva Maneuver in Pulmonary Arterial Hypertension. Chest, 2016, 149, 1252-1260.	0.4	23
33	Desmoplakin Variants Are Associated with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1151-1160.	2.5	68
34	Bone Marrowâ€“derived Cells Contribute to the Pathogenesis of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 898-909.	2.5	60
35	Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 464-475.	2.5	69
36	A Phenome-Wide Association Study Identifies a Novel Asthma Risk Locus NearTERC. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 98-100.	2.5	4

#	Article	IF	Citations
37	Estrogen Metabolite 16Î±-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type IIâ€“Associated Pulmonary Arterial Hypertension Through MicroRNA-29â€“Mediated Modulation of Cellular Metabolism. Circulation, 2016, 133, 82-97.	1.6	83
38	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Human Mutation, 2015, 36, 1113-1127.	1.1	185
39	Telomeres revisited: RTEL1 variants in pulmonary fibrosis. European Respiratory Journal, 2015, 46, 312-314.	3.1	12
40	Toward Precision Medicine in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1272-1274.	2.5	8
41	Rare Variants in RTEL1 Are Associated with Familial Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 646-655.	2.5	170
42	Serum Endostatin Is a Genetically Determined Predictor of Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 208-218.	2.5	92
43	Extensive Phenotyping of Individuals at Risk for Familial Interstitial Pneumonia Reveals Clues to the Pathogenesis of Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 417-426.	2.5	141
44	The genetic basis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1717-1727.	3.1	160
45	Fibrosing mediastinitis complicating prior histoplasmosis is associated with human leukocyte antigen DQB1*04:02â€‰â^'â€‰a case control study. BMC Infectious Diseases, 2015, 15, 206.	1.3	15
46	Histoplasmosis: Up-to-Date Evidence-Based Approach to Diagnosis and Management. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 729-745.	0.8	115
47	Letter by Mosley Regarding Article, â€œIron Homeostasis and Pulmonary Hypertension: Iron Deficiency Leads to Pulmonary Vascular Remodeling in the Ratâ€• Circulation Research, 2015, 117, e56-7.	2.0	2
48	Further Progress in Understanding Fibrosing Mediastinitis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 767-768.	2.5	5
49	Enhanced caveolin-1 expression in smooth muscle cells: Possible prelude to neointima formation. World Journal of Cardiology, 2015, 7, 671.	0.5	13
50	Identification of a common Wnt-associated genetic signature across multiple cell types in pulmonary arterial hypertension. American Journal of Physiology - Cell Physiology, 2014, 307, C415-C430.	2.1	64
51	Functional Prostacyclin Synthase Promoter Polymorphisms. Impact in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1110-1120.	2.5	15
52	ABCG2^{pos}lung mesenchymal stem cells are a novel pericyte subpopulation that contributes to fibrotic remodeling. American Journal of Physiology - Cell Physiology, 2014, 307, C684-C698.	2.1	79
53	An evidence-based knowledgebase of pulmonary arterial hypertension to identify genes and pathways relevant to pathogenesis. Molecular BioSystems, 2014, 10, 732-740.	2.9	16
54	The Genetics of Pulmonary Arterial Hypertension. Circulation Research, 2014, 115, 189-202.	2.0	148

#	Article	IF	Citations
55	Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 214-222.	2.5	199
56	Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension. Drug Discovery Today, 2014, 19, 1241-1245.	3.2	24
57	A Novel Dyskerin (DKC1) Mutation Is Associated With Familial Interstitial Pneumonia. Chest, 2014, 146, e1-e7.	0.4	125
58	A Novel Channelopathy in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 351-361.	13.9	412
59	Heritable and Idiopathic Forms of Pulmonary Arterial Hypertension. , 2013, , 1-20.		0
60	Interstitial and Restrictive Pulmonary Disorders. , 2013, , 1-22.		2
61	How I Treat Histoplasmosis. Current Fungal Infection Reports, 2013, 7, 36-43.	0.9	11
62	Genetics and Genomics of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D13-D21.	1.2	367
63	An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 733-748.	2.5	3,134
64	Prostanoids But Not Oral Therapies ImproveÂRight Ventricular Function in Pulmonary Arterial Hypertension. JACC: Heart Failure, 2013, 1, 300-307.	1.9	31
65	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nature Genetics, 2013, 45, 518-521.	9.4	93
66	Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nature Genetics, 2013, 45, 613-620.	9.4	667
67	MUC5B Promoter Polymorphism and Interstitial Lung Abnormalities. New England Journal of Medicine, 2013, 368, 2192-2200.	13.9	358
68	Shorter Survival in Familial versus Idiopathic Pulmonary Arterial Hypertension is Associated with Hemodynamic Markers of Impaired Right Ventricular Function. Pulmonary Circulation, 2013, 3, 589-598.	0.8	30
69	Interaction between Bone Morphogenetic Protein Receptor Type 2 and Estrogenic Compounds in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 564-577.	0.8	47
70	Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2013, 309, 2232.	3.8	395
71	Heritable Forms of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 568-580.	0.8	20
72	Histoplasmomas of Uncommon Size. Chest, 2013, 143, 1795-1798.	0.4	7

#	Article	IF	Citations
73	Bronchoscopic Cryobiopsy for the Diagnosis of Diffuse Parenchymal Lung Disease. PLoS ONE, 2013, 8, e78674.	1.1	128
74	Mast Cell Number, Phenotype, and Function in Human Pulmonary Arterial Hypertension. Pulmonary Circulation, 2012, 2, 220-228.	0.8	55
75	Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension. Circulation: Cardiovascular Genetics, 2012, 5, 336-343.	5.1	333
76	Connectivity Map Analysis of Nonsense-Mediated Decayâ€“Positive BMPR2-Related Hereditary Pulmonary Arterial Hypertension Provides Insights into Disease Penetrance. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 20-27.	1.4	16
77	Longitudinal Analysis Casts Doubt on the Presence of Genetic Anticipation in Heritable Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 892-896.	2.5	178
78	Pulmonary vascular disease in mice xenografted with human BM progenitors from patients with pulmonary arterial hypertension. Blood, 2012, 120, 1218-1227.	0.6	68
79	Intratracheal bleomycin causes airway remodeling and airflow obstruction in mice. Experimental Lung Research, 2012, 38, 135-146.	0.5	28
80	Pre-implantation genetic testing for hereditary pulmonary arterial hypertension: promise and caution. European Respiratory Journal, 2012, 39, 1292-1293.	3.1	4
81	High-Resolution CT Scan Findings in Familial Interstitial Pneumonia Do Not Conform to Those of Idiopathic Interstitial Pneumonia. Chest, 2012, 142, 1577-1583.	0.4	63
82	Role of BMPR2 Alternative Splicing in Heritable Pulmonary Arterial Hypertension Penetrance. Circulation, 2012, 126, 1907-1916.	1.6	65
83	Loss-of-function thrombospondin-1 mutations in familial pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2012, 302, L541-L554.	1.3	43
84	BMPR2 expression is suppressed by signaling through the estrogen receptor. Biology of Sex Differences, 2012, 3, 6.	1.8	103
85	Potential Interventions Against BMPR2-Related Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2012, 11, 25-32.	0.1	2
86	Chasing Pulmonary Hypertension: 1980â€“2012. Advances in Pulmonary Hypertension, 2012, 11, 121-123.	0.1	0
87	A CommonMUC5BPromoter Polymorphism and Pulmonary Fibrosis. New England Journal of Medicine, 2011, 364, 1503-1512.	13.9	986
88	Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respiratory Medicine, 2011, 105, 1902-1907.	1.3	141
89	Ancestral Mutation in Telomerase Causes Defects in Repeat Addition Processivity and Manifests As Familial Pulmonary Fibrosis. PLoS Genetics, 2011, 7, e1001352.	1.5	99
90	Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood, 2011, 117, 3485-3493.	0.6	118

#	Article	IF	Citations
91	Genetics in Pulmonary Fibrosisâ€"Familial Cases Provide Clues to the Pathogenesis of Idiopathic Pulmonary Fibrosis. American Journal of the Medical Sciences, 2011, 341, 439-443.	0.4	53
92	Physiologic and molecular consequences of endothelial Bmpr2 mutation. Respiratory Research, 2011, 12, 84.	1.4	54
93	Decreased dyskerin levels as a mechanism of telomere shortening in X-linked dyskeratosis congenita. Journal of Medical Genetics, 2011, 48, 327-333.	1.5	55
94	Pulmonary Arterial Hypertension: Insights from Genetic Studies. Proceedings of the American Thoracic Society, 2011, 8, 154-157.	3.5	18
95	Percutaneous Vascular Stent Implantation as Treatment for Central Vascular Obstruction Due to Fibrosing Mediastinitis. Circulation, 2011, 123, 1391-1399.	1.6	67
96	Idiopathic and Heritable PAH Perturb Common Molecular Pathways, Correlated with Increased MSX1 Expression. Pulmonary Circulation, 2011, 1, 389-398.	0.8	27
97	The Genetics of Pulmonary Arterial Hypertension in the Postâ€BMPR2 Era. Pulmonary Circulation, 2011, 1, 305-319.	0.8	52
98	Programmatic change: lung disease research in the era of induced pluripotency. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2011, 301, L830-L835.	1.3	6
99	Genetics of Familial and Idiopathic Pulmonary Arterial Hypertension. , 2011, , 997-1009.		0
100	Ventricular Geometry, Strain, and Rotational Mechanics in Pulmonary Hypertension. Circulation, 2010, 121, 259-266.	1.6	216
101	A Case Series and Review of Histoplasmosis Infection in the Neck. JAMA Otolaryngology, 2010, 136, 916.	1.5	8
102	Identification of Early Interstitial Lung Disease in an Individual With Genetic Variations in ABCA3 and SFTPC. Chest, 2010, 137, 969-973.	0.4	88
103	Will the Genes Responsible for Familial Pulmonary Fibrosis Provide Clues to the Pathogenesis of IPF?. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1342-1343.	2.5	9
104	Obstructive Sleep Apnea Is Common in Idiopathic Pulmonary Fibrosis. Chest, 2009, 136, 772-778.	0.4	281
105	Genetics of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 386-398.	0.8	43
106	A Functional Single-Nucleotide Polymorphism in theTRPC6Gene Promoter Associated With Idiopathic Pulmonary Arterial Hypertension. Circulation, 2009, 119, 2313-2322.	1.6	173
107	Penetrance of pulmonary arterial hypertension is modulated by the expression of normalBMPR2allele. Human Mutation, 2009, 30, 649-654.	1.1	102
108	Copy-number variation in BMPR2 is not associated with the pathogenesis of pulmonary arterial hypertension. BMC Medical Genetics, 2009, 10, 58.	2.1	4

#	Article	IF	Citations
109	Longâ€term outcomes of cytomegalovirus infection and disease after lung or heartâ€“lung transplantation with a delayed ganciclovir regimen. Clinical Transplantation, 2009, 23, 476-483.	0.8	20
110	Diagnosis and Assessment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S55-S66.	1.2	984
111	Genetics and Genomics of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S32-S42.	1.2	342
112	Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension. Respiratory Research, 2009, 10, 87.	1.4	91
113	Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13051-13056.	3.3	665
114	Proteomics of Transformed Lymphocytes from a Family with Familial Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 99-107.	2.5	20
115	Pulmonary Histoplasmosis. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 151-165.	0.8	60
116	Synergistic heterozygosity for TGFÎ²1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension. Genetics in Medicine, 2008, 10, 359-365.	1.1	69
117	Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 294, L1119-L1126.	1.3	377
118	Narrative Review: The Enigma of Pulmonary Arterial Hypertension: New Insights from Genetic Studies. Annals of Internal Medicine, 2008, 148, 278.	2.0	83
119	External-Beam Radiotherapy for Massive Hemoptysis Complicating Mediastinal Fibrosis. Southern Medical Journal, 2008, 101, 1056-1058.	0.3	4
120	Acute Exacerbations of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 636-643.	2.5	996
121	Computed Tomography and the Idiopathic Form of Proliferative Fibrosing Mediastinitis. Journal of Thoracic Imaging, 2007, 22, 235-240.	0.8	24
122	Current diagnosis and management of idiopathic pulmonary fibrosis: A survey of academic physicians. Respiratory Medicine, 2007, 101, 2011-2016.	1.3	38
123	Long-term Follow-up After Conversion from Intravenous Epoprostenol to Oral Therapy With Bosentan or Sildenafil in 13 Patients With Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2007, 26, 363-369.	0.3	29
124	Genetics and Mediators in Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 2007, 28, 43-57.	0.8	48
125	Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2007, 45, 807-825.	2.9	1,148
126	Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2007, 356, 1317-1326.	13.9	1,175

#	Article	IF	Citations
127	Serotonin Transporter Polymorphisms in Familial and Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 798-802.	2.5	83
128	The Genetic Approach in Pulmonary Fibrosis: Can It Provide Clues to This Complex Disease?. Proceedings of the American Thoracic Society, 2006, 3, 345-349.	3.5	67
129	High Frequency ofBMPR2Exonic Deletions/Duplications in Familial Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 590-598.	2.5	192
130	Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 291, L694-L702.	1.3	54
131	Aberrant Signal Transduction In Pulmonary Hypertension. Chest, 2005, 128, 564S-565S.	0.4	10
132	Prostacyclin Synthase Promoter Regulation and Familial Pulmonary Arterial Hypertension. Chest, 2005, 128, 612S.	0.4	14
133	Clinical and Pathologic Features of Familial Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1146-1152.	2.5	381
134	Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genetics in Medicine, 2005, 7, 169-174.	1.1	107
135	Characterization of Fibroblast-specific Protein 1 in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 899-907.	2.5	168
136	Pulmonary Histoplasmosis Syndromes: Recognition, Diagnosis, and Management. Seminars in Respiratory and Critical Care Medicine, 2004, 25, 129-144.	0.8	128
137	Genetic basis of pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S33-S39.	1.2	227
138	Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension. Chest, 2004, 126, 14S-34S.	0.4	799
139	Primary pulmonary hypertension. Lancet, The, 2003, 361, 1533-1544.	6.3	496
140	A modified bronchial anastomosis technique for lung transplantation. Annals of Thoracic Surgery, 2003, 75, 1697-1704.	0.7	35
141	Herpesvirus DNA Is Consistently Detected in Lungs of Patients with Idiopathic Pulmonary Fibrosis. Journal of Clinical Microbiology, 2003, 41, 2633-2640.	1.8	276
142	Outcome in 91 Consecutive Patients with Pulmonary Arterial Hypertension Receiving Epoprostenol. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 580-586.	2.5	229
143	Pulmonary Veno-occlusive Disease Caused by an Inherited Mutation in Bone Morphogenetic Protein Receptor II. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 889-894.	2.5	135
144	Pulmonary fibrosis in families. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, S47-50.	1.4	65

#	Article	IF	Citations
145	Heterozygosity for a Surfactant Protein C Gene Mutation Associated with Usual Interstitial Pneumonitis and Cellular Nonspecific Interstitial Pneumonitis in One Kindred. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1322-1328.	2.5	597
146	Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy1. Transplantation, 2002, 74, 79-84.	0.5	56
147	Genetics and Gene Expression in Pulmonary Hypertension. Chest, 2002, 121, 46S-50S.	0.4	11
148	Genetics and Pulmonary Hypertension*. Chest, 2002, 122, 284S-286S.	0.4	16
149	Prevention of Cytomegalovirus Infection and Disease After Lung Transplantation. Chest, 2002, 121, 407-414.	0.4	21
150	Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis. Respiratory Research, 2002, 3, 17.	1.4	31
151	BMPR2 Haploinsufficiency as the Inherited Molecular Mechanism for Primary Pulmonary Hypertension. American Journal of Human Genetics, 2001, 68, 92-102.	2.6	521
152	GENETICS OF PRIMARY PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 477-491.	0.8	23
153	Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension. Circulation Research, 2001, 88, 555-562.	2.0	256
154	Iatrogenic Paradoxical Air Embolism in Pulmonary Hypertension. Chest, 2001, 119, 1602-1605.	0.4	21
155	Is Vasculitis an Early Pathogenic Mechanism of Interstitial Pulmonary Fibrosis?. Chest, 2001, 120, S57.	0.4	0
156	Idiopathic Pulmonary Fibrosis Can Be an Autosomal Dominant Trait in Some Families. Chest, 2001, 120, S56.	0.4	16
157	Pulmonary Artery Stenosis and Fibrous Mediastinitis. Chest, 2001, 120, 1750-1751.	0.4	5
158	Estimation and visualization of regional and global pulmonary perfusion with 3D magnetic resonance angiography. Journal of Magnetic Resonance Imaging, 2001, 14, 734-740.	1.9	9
159	Clinical and Molecular Genetic Features of Pulmonary Hypertension in Patients with Hereditary Hemorrhagic Telangiectasia. New England Journal of Medicine, 2001, 345, 325-334.	13.9	676
160	Mutation in the Gene for Bone Morphogenetic Protein Receptor II as a Cause of Primary Pulmonary Hypertension in a Large Kindred. New England Journal of Medicine, 2001, 345, 319-324.	13.9	351
161	Percutaneous Pulmonary Artery and Vein Stenting. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 657-660.	2.5	84
162	Respiratory Bronchiolitis Associated With Severe Dyspnea, Exertional Hypoxemia, and Clubbing. Chest, 2000, 117, 282-285.	0.4	35

#	Article	IF	Citations
163	Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. Annals of Internal Medicine, 2000, 132, 425.	2.0	905
164	Heterozygous germline mutations in BMPR2, encoding a TGF-Î² receptor, cause familial primary pulmonary hypertension. Nature Genetics, 2000, 26, 81-84.	9.4	1,388
165	Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus Erythematosus. Chest, 2000, 117, 14-18.	0.4	109
166	Mediastinal Fibrosis Is Associated With Human Leukocyte Antigen-A2. Chest, 2000, 117, 482-485.	0.4	39
167	Active CMV infection before lung transplantation: risk factors and clinical implications. Journal of Heart and Lung Transplantation, 2000, 19, 744-750.	0.3	17
168	Lung allocation in the United States, 1995â€“1997: an analysis of equity and utility. Journal of Heart and Lung Transplantation, 2000, 19, 846-851.	0.3	17
169	Quantitative 3D VUSE pulmonary MRA. Magnetic Resonance Imaging, 1999, 17, 363-370.	1.0	7
170	Pulmonary Vein Stenosis After Catheter Ablation of Atrial Fibrillation. Circulation, 1998, 98, 1769-1775.	1.6	437
171	Genetics and Immunogenetic Aspects of Primary Pulmonary Hypertension. Chest, 1998, 114, 231S-236S.	0.4	21
172	A Survey of Diagnostic Practices and the Use of Epoprostenol In Patients With Primary Pulmonary Hypertension. Chest, 1998, 114, 1269-1275.	0.4	79
173	The Presence of Genetic Anticipation Suggests That the Molecular Basis of Familial Primary Pulmonary Hypertension May Be Trinucleotide Repeat Expansion. Chest, 1997, 111, 82S-83S.	0.4	24
174	Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31â€“32. Nature Genetics, 1997, 15, 277-280.	9.4	260
175	An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary Hypertension. New England Journal of Medicine, 1992, 327, 70-75.	13.9	1,083
176	Heterogeneity of Pathologic Lesions in Familial Primary Pulmonary Hypertension. The American Review of Respiratory Disease, 1988, 138, 952-957.	2.9	96
177	Mediastinal Fibrosis Complicating Histoplasmosis. Medicine (United States), 1988, 67, 295-310.	0.4	203
178	Histoplasmosis in Normal Hosts. Medicine (United States), 1981, 60, 231-266.	0.4	265